Systemic sclerosis & Raynaud's
Anti-cytolethal distending toxin antibodies in systemic sclerosis: associations with gastrointestinal disease and immune dysregulation
Authors' conclusion
Anti-CDT antibodies may serve as markers of post-infectious autoimmunity and strongly associate with SSc-autoantibodies linked to severe, progressive GI disease.
Study context
- Population
- Large, well-characterized cohort of systemic sclerosis (SSc) patients enriched for gastrointestinal (GI) diseaseenriched for GI disease
- Participants
- 130 participants
- Exposure
- Anti-CDT positive vs anti-CDT negative SSc patients
- Anti-CDT positiven = 23
- Outcome
- Prevalence of anti-CDT antibodies
Methodological detailslinear mixed-effects models, multivariable analyses
- Linear mixed-effects models
- Multivariable analyses
Main finding
As reported in the abstract
Anti-CDT antibody prevalence
Anti-CDT antibodies detected (23/130)
18%
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Anti-U11/U12 (RNPC3) antibodiesAnti-CDT positivevs Anti-CDT negativeMultivariable, adjusted for confounders | 19.0 (4.3–83.4) | P ≤ 0.001 | |
| Anti-U1RNP antibodiesAnti-CDT positivevs Anti-CDT negativeMultivariable, adjusted for confounders | 7.2 (1.9–27.9) | P = 0.004 | |
| Anti-topoisomerase-1 antibodiesAnti-CDT positivevs Anti-CDT negativeMultivariable, adjusted for confounders | 4.7 (1.3–16.8) | P = 0.019 | |
| 0.050.21520Odds ratio (log scale) |
| Outcome | Anti-CDT positive | P value |
|---|---|---|
| Significant GI diseaseAnti-CDT positive vs Anti-CDT negative | 87% | P = 0.19 |
| Anti-U11/U12 (RNPC3) antibodiesAnti-CDT positive vs Anti-CDT negative | 35% | P < 0.001 |
| Anti-U1RNP antibodiesAnti-CDT positive vs Anti-CDT negative | 26% | P = 0.018 |
| Anti-topoisomerase-1 antibodiesAnti-CDT positive vs Anti-CDT negative | 30% | P = 0.044 |
| UCLA GIT Soilage scoreAnti-CDT positive vs Anti-CDT negative | median 1 (IQR 1–2) | P = 0.037 |
- Significant GI disease: Anti-CDT negative 71%
- Anti-U11/U12 (RNPC3) antibodies: Anti-CDT negative 4%
- Anti-U1RNP antibodies: Anti-CDT negative 8%
- Anti-topoisomerase-1 antibodies: Anti-CDT negative 12%
- UCLA GIT Soilage score: Anti-CDT negative median 0 (IQR 0–2)
Anti-CDT titres over time
- Anti-CDT titres did not change significantly over time
Original publication
Anti-cytolethal distending toxin antibodies in systemic sclerosis: associations with gastrointestinal disease and immune dysregulation. Rheumatology (Oxford). Published 10 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →